secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070385
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q1 revenue $11.9M, positive adj EBITDA $0.4M after $10M strategic investment
--------------------------------------------------------------------------------

- Total revenue $11.9M (flat YoY); Cyclo G6 glaucoma revenue up 8% to $3.2M; Retina revenue down 3% to $6.6M.
- Adjusted EBITDA improved to $0.4M from ($2.5M) YoY; net loss narrowed to $1.7M ($0.10/share) from $3.5M ($0.21).
- Operating expenses cut 32% to $5.3M; gross margin expanded to 42.5% from 37.9% on favorable product mix.
- Received $10M strategic investment from Novel Inspiration; Lind note payable settled, reducing debt.
- 2025 outlook: cash flow breakeven and positive adjusted EBITDA on 2024-level revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017025070385/0000950170-25-070385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017025070385/irix-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer